




Vasodilator and Inotropic Therapy for Severe Chronic Heart Failure:
Passion and Skepticism
MILTON PACKER, MD, FACC
New York, New York
Although substantial progress has been made in the last
5 years in the development of vasodilator and inotropic
drugs for the management of patients with severechronic
heart failure, much of the enthusiasm that surrounded
the introduction of many of these agents has subse-
quently been tempered by reports of drug failure or
adverse reactions. In this review and analysis, currently
available vasodilator and inotropic agents are critically
and comparatively evaluated to assess their respective
advantages and limitations.
It is apparent that the ability of most of these drugs
to produce substantial clinical benefits in patients with
severe heart failure has probably been overstated. Ther-
apy fails to achieve the desired clinical results all too
frequently, possibly as the result of: the choice of an
Passion makes the best observations and draws the most
wretched conclusions.
Richter
Nothing fortifies skepticism more than that there are some
who are not skeptics; if all were so, they would be
wrong.
Pascal
Five years ago when orally active systemic vasodilator drugs
were first being used for the management of patients with
severe chronic heart failure, we reviewed the advantages
and disadvantages of the drugs available at that time and
appealed for caution (1), because no single drug or drug
combination appeared to fulfill the prerequisites of efficacy
and safety that were needed before this therapeutic approach
could be recommended for widespread use. Over the last 5
years, however, substantial progress has been made, new
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ineffective drug; the administration of an effective drug
in subtherapeutic doses; the administration of an effec-
tive drug to improperly selected patients; the failure of
initial hemodynamic benefits to be sustained; the occur-
rence of severe or serious adverse reactions; and the
failure to alter concomitant therapy appropropriately.
The present analysis indicates that there is no uni-
formly effectiveor safe vasodilator or inotropic drug for
patients with severe heart failure; all agents have im-
portant limitations. Of the available therapeutic choices,
however, long-term converting enzyme inhibition ap-
pears to produce more consistent hemodynamic and clin-
ical benefits with an acceptable degree of adverse re-
actions than other pharmacologic approaches for the
management of these severely ill patients.
vasodilator and inotropic agents have been developed and
the enthusiasm surrounding the use of these drugs is greater
than ever. Hence, it is appropriate to reexamine the advan-
tages and limitations of existing therapeutic approaches for
severe chronic heart failure and ask: Is the caution we ad-
vised in our original review still warranted?
The number of orally active vasodilator drugs that have
been advocated for use in chronic heart failure has multiplied
dramatically in the last 5 years (Table 1) (2), The list now
includes: the direct-acting vasodilator agents: nitrates, hy-
dralazine and minoxidil; the neurohumoral antagonists: pra-
zosin, trimazosin, captopril and enalapril; the calcium chan-
nel antagonists: nifedipine, verapamil and diltiazem; the
beta-adrenergic agonist drugs with vasodilator activity:
prenalterol, pirbuterol, salbutamol and terbutaline; and the
noncatecholamine nonglycoside inotropic drugs with vaso-




Therapeutic properties. Orally active nitrates, partic-
ularly isosorbide dinitrate, were the first oral vasodilator
drugs widely used in the management of patients with severe
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chronic heart failure (3). Nitrates primarily lower right and
left ventricular filling pressures by a direct dilating action
on venous capacitance vessels (4-7); the immediate in-
creases in cardiac output are usually small but may be great
in specific clinical situations, such as, after the administra-
tion of large doses (40 to 100 mg orally [8]), in patients
having a very low cardiac index before treatment (9,10) and
in patients with severe mitral or aortic valve regurgitation
(II). The initial beneficial hemodynamic effects at rest are
also observed during exercise (12,13), dyspnea and fatigue
are alleviated and exercise tolerance improves (14-17). Two
double-blind randomized clinical trials in patients with se-
vere heart failure (14,15) have demonstrated that long-term
treatment with nitrates (isosorbide dinitrate, 160 mg orally
daily for 3 months) produces significant hemodynamic and
clinical improvement compared with treatment with pla-
cebo. Furthermore, nitrates are well tolerated; headaches,
flushing and dizziness occur less frequently in patients with
heart failure than in patients with angina pectoris, and few
patients with heart failure discontinue nitrates because of
adverse reactions.
Limitations and disadvantages. Tolerance develops to
the hemodynamic effects of nitrates during long-term ther-
apy in some patients with heart failure, but the frequency
of its occurrence is not known. Leier et al. (15) have shown
that during long-term treatment, tolerance occurs primarily
to the arterial vasodilating actions of these agents, but not
to their effects on venous capacitance. Accordingly, sus-
tained decreases in right and left ventricular filling pressures
during rest and exercise without increases in cardiac output
occur in most patients receiving long-term nitrate therapy
(15,16). However, the lack of improvement in cardiac out-
put appears to be clinically unimportant because exercise
tolerance improves even in the absence of an increase in
forward flow (15,17). Maximal oxygen consumption is en-
hanced during long-term treatment with nitrates despite little
change in oxygen delivery to the peripheral circulation be-
cause systemic oxygen extraction is increased by the training
effects of more comfortable repeated submaximal exercise
(17). Because the short-term effects of these drugs on car-
diac output appear to be of minor significance, the concern
about the use of nitrates in patients with low ventricular
filling pressures before therapy may not be warranted. Al-
though cardiac output may decline in these patients as pre-
load is excessively compromised (18,19), nitrates will ef-
fectively attenuate exercise-induced increases in ventricular
filling pressure (12,13) and reduce exertional dyspnea, re-
gardless of the pretreatment level of filling pressure. This
attenuation leads to an improvement in peripheral oxygen
extraction and exercise tolerance during long-term therapy
(by means of a training effect), regardless of the observed
direction and magnitude of acute changes in cardiac output
at rest (20).
The effectiveness of short- and long-term therapy with
nitrates administered by other than oral routes (for example,
transcutaneous delivery) remains unproven. Preliminary
evidence (21) suggests that continuous nitroglycerin therapy
may result in the rapid development of tolerance to the
drug's beneficial hemodynamic effects, and this may be
followed by rebound hemodynamic changes after the drug
is withdrawn. Rebound events may follow the abrupt dis-
continuation of long-term oral nitrate therapy as well (14).
Clinical perspective. Present evidence indicates that
oral nitrates are effective drugs in the treatment of severe
chronic heart failure. Furthermore, these agents are easy to
use, hemodynamic responses are usually sustained during
chronic therapy and adverse effects requiring discontinua-
tion of treatment are infrequent (Table 2). However, in our
experience, the clinical benefits that accompany short- and
long-term nitrate therapy are modest compared with those
observed with other vasodilator drugs; most patients con-
tinue to experience disabling symptoms of heart failure,
even though some improvement may have been experi-
enced. Hence, many clinicians use nitrates as adjuvant ther-
apy to other orally effective vasodilator drugs (22,23).
Hydralazine
Therapeutic properties. Because of its predominant di-
rect arterial vasodilator actions, hydralazine primarily in-
creases cardiac output and lowers systemic vascular resist-
ance in patients with severe chronic heart failure (24,25).
Although venous capacitance is minimally altered (25), left
ventricular filling pressures may be markedly decreased by
lACC Vol 2, No.5
November 1983:841-52
PACKER
VASODILATOR THERAPY FOR HEART FAILURE
843
Table 2. Advantages and Lirmtations of Orally Active Vasodilator and Inotropic Drugs in Severe Chronic Heart Failure
Calcium Beta-Receptor Noncatecholamine
Nitrates Hydralazine Prazosm Captopril Antagonists Agorusts Inotropes
Dose requirements Fairly Vanable Fairly Fairly Variable Vanable Variable
uniform Uniform Uniform
Initial hernodynarruc response Usually May be Usually May be May be May be Usually
favorable detrimental favorable detnmental detnmental detrimental favorable
Hemodynamic tolerance Occasional, Occasional Common Uncommon Unknown Common Unknown
arterial (-30%) (-50%) (-15%)
Adverse reactions Occasional, Common, may Uncommon, Occasional, Common, may Common, may Common, may
mild be severe mild manageable be severe be severe be severe
Overall efficacy Unknown 30 to 40% 30 to 40% -60% Unknown Probably Unknown
meffective
hydralazine in patients with severe mitral or aortic valve
regurgitation in whom aortic impedence plays a critical role
in determining the magnitude of regurgitant volume (26,27).
Hydralazine's benefits are seen at rest and during exercise
(28); in patients with a markedly dilated congestive cardio-
myopathy with associated secondary valvular regurgitation,
long-term hydralazine therapy lessens dyspnea and fatigue
and enhances exercise tolerance (29,30), However, in most
reports (22,23,30-33), hydralazine has not been the sole
vasodilator drug used, but has usually been combined with
nitrates, Because nitrates are effective alone (14,15), it is
unclear to what extent the reported benefits with combined
therapy are the result of concomitant drug treatment; in other
words, it is uncertain to what extent hydralazine adds to the
improvement expected after therapy with nitrates alone.
Limitations and disadvantages. At Mount Sinai Hos-
pital, we have used hydralazine as monotherapy for patients
with severe heart failure for the past 7 years and have found
that the hemodynamic and clinical responses to the drug
vary greatly, Although some patients show marked clinical
improvement, the therapeutic application of this drug has
important disadvantages:
I) The dose requirements of hydralazine are highly vari-
able (34,35). Although many patients respond favorably to
a dose of 300 mg daily, patients will frequently require
larger doses (400 to 3,000 mg daily) to produce hemody-
namic effects; conversely, some patients may be exquisitely
sensitive to small doses (35). The administration of an ar-
bitrary dose of the drug (for example, 300 mg orally) may
be subtherapeutic for some patients and excessive for others.
Because empiric dose titration based on clinical symptoms
is difficult, invasive hemodynamic testing appears manda-
tory to ensure the administration of effective doses of the
drugs (36).
2) Even if pharmacologically effective quantities of hy-
dralazine are administered, the hemodynamic and clinical
responses to the drug still vary greatly, Patients with a
markedly dilated left ventricle show marked increases in
cardiac index and stroke work with minimal hypotension or
tachycardia; these patients improve clinically with long-term
hydralazine therapy as prerenal azotemia resolves (29), On
the other hand, patients with small left ventricular dimen-
sions show only modest hemodynamic benefits, and these
are accompanied by marked decreases in blood pressure and
increases in heart rate; during long-term treatment with hy-
dralazine, such patients fail to improve symptomatically and
some may show clinical deterioration (progressive lethargy
and confusion, worsening azotemia and ventricular arrhyth-
mias) (29),
3) Even if effective doses ofhydralazine are administered
and highly favorable hemodynamic responses are obtained,
long-term clinical improvement may not be observed, This
may occur in part because pharmacologic tolerance may
develop to the initial beneficial effects of the drug during
prolonged administration (37), Of 104 consecutive patients
whose acute responses to hydralazine were confirmed by
right heart catheterization, we identified 38 patients with
marked initial favorable hemodynamic effects, who inexplic-
ably failed to show improvement during long-term treat-
ment When the hemodynamic responses to hydralazine were
reassessed in 11 of these patients after an average of 37
weeks of therapy, we found that the marked increases in
cardiac output seen initially were no longer present and that
hemodynamic variables had returned to prehydralazine val-
ues, Tolerance could not be reversed by increments in the
dose of the drug, by its intravenous administration or by
diuresis; furthermore, deterioration did not occur when the
drug was withdrawn (37), In contrast, long-term clinical
benefits with hydralazine are usually seen in patients who
demonstrate sustained hemodynamic effects (30,38,39), On
the basis of these data, we estimate that clinically important
tolerance occurs in about 30% of patients with heart failure
who receive long-term treatment with hydralazine,
4) Even when sustained hemodynamic and clinical ben-
efits are seen with hydralazine, adverse reactions may occur
that may warrant discontinuation of effective therapy. In
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our experience, these appear to be more frequent with hy-
dralazine than with most other vasodilator drugs used in the
treatment of severe chronic heart failure. There are four
adverse reactions that deserve special mention. Headaches,
palpitation and flushing occur in about one-third of patients
and may be severe, but are usually short-lived « 1 week)
and are almost never a cause for withdrawal of treatment.
Nausea and vomiting occur occasionally, probably related
to large oral doses required to produce hemodynamic effects
and are the most common reasons for discontinuation of
therapy. Myocardial ischemic events (unstable angina and
myocardial infarction) may occur during initiation of treat-
ment with hydralazine and are the most feared complications
of therapy (40). Systemic lupus erythematosus may be in-
duced when large doses of hydralazine are given for long
periods to patients for treatment of systemic hypertension
(41). However, this has been a minor problem with the use
of hydralazine in the treatment of patients with heart failure,
probably because the duration of therapy required to produce
this syndrome may exceed the life expectancy of many
patients with severe left ventricular dysfunction (32,33,42).
Clinical perspective. Because of these disadvantages
(Table 2), we do not use hydralazine as a first line vaso-
dilator drug for patients with severe chronic heart failure,
except for patients with severe aortic regurgitation who are
particularly sensitive to the modest decreases in aortic
impedance achievable with small doses of the drug (27).
The only randomized controlled clinical trial (43) using
hydralazine as monotherapy failed to show significant dif-
ferences between placebo- and hydralazine-treated patients;
this supports our own experience, in which only 30 to 40%
of consecutively evaluated patients with heart failure ben-
efited from long-term treatment with the drug.
Minoxidil
A direct-acting arterial vasodilator drug similar to hy-
dralazine, minoxidil, produces short- and long-term hemo-
dynamic improvement in many patients with severe heart
failure (44,45). Compared with hydralazine, however, min-
oxidil may have some advantages: the dose requirements of
the drug appear to be more uniform (most patients respond
to 20 mg twice daily [44]), and tolerance may occur less
frequently (many patients who develop tolerance to hy-
dralazine are still responsive to minoxidil [37,46]). How-
ever, experience with minoxidil in severe chronic heart fail-
ure remains limited, and it is not certain that clinical benefits
are seen even when initial hemodynamic responses are sus-
tained (45). Furthermore, adverse reactions (particularly fluid
retention) are more frequent with minoxidil than with hy-
dralazine (46,47). Such fluid retention is frequently severe
and may be resistant to large doses of furosemide; in our
experience, the addition of metolazone may be particularly
helpful in such patients.
Neurohumoral Antagonists
Prazosin
Therapeutic properties. By attenuating the effects of
the sympathetic nervous system on the peripheral circulation
(48), the postsynaptic alpha-adrenergic blocking agent, pra-
zosin, produces marked beneficial hemodynamic effects
during the administration of first doses of the drug (49,50).
These responses generally are highly favorable and do not
appear to be dose-dependent; presumably, once complete
alpha-receptor blockade is achieved, further increments in
dose do not result in further postsynaptic receptor inhibition
(51). Moreover, long-term therapy with prazosin over a
wide range of doses (6 to 15 mg daily orally) is well tol-
erated; adverse reactions are uncommon. The first dose diz-
ziness and syncope described in hypertensive patients (52-54),
which probably resulted from an excessive lowering of nor-
mal left ventricular filling pressures, rarely occurs in patients
with severe heart failure, whose filling pressures are mark-
edly elevated before treatment.
Limitations and disadvantages. Considerable concern
has been expressed, however, about the long-term effec-
tiveness of prazosin in patients with severe heart failure.
Although first doses of prazosin produce marked beneficial
hemodynamic responses, these effects become rapidly at-
tenuated within 48 hours of continuous therapy with the
drug (55-58). The fate and clinical significance of this short-
term tachyphylaxis have become a matter of considerable
dispute. Some investigators (59,60) have suggested that
hemodynamic tolerance to prazosin may occur only at rest
and not during exercise. However, studies (61) of the long-
term effects of the drug during exertion have demonstrated
a pattern of attenuation similar to that seen at rest. Some
investigators (58,62) have suggested that short-term toler-
ance to prazosin is spontaneously reversible and that long-
term effects may exceed the benefits seen with first doses
of the drug. In our experience (63), early hemodynamic
tolerance is rarely reversible and is not responsive to incre-
ments in the dose of prazosin or that of concomitantly ad-
ministered diuretic agents. Still other investigators have pos-
tulated that long-term tolerance may not be the result of a
loss of the pharmacologic actions of prazosin, but a con-
sequence of activation of counterposing neurohumoral forces,
(the sympathetic nervous system or renin-angiotensin sys-
tem) (51,64,65), so that tolerance may be reversed or pre-
vented by treatment with aldosterone antagonists (62,66).
However, in our experience as well as that of others, sus-
tained increases in plasma renin activity or in plasma cate-
cholamines are not seen during long-term prazosin therapy
(67), and tolerance is not prevented or reversed by spiro-
nolactone (63).
The controversy concerning the effectiveness of prazosin
in heart failure is reflected by the results of double-blind
placebo-controlled trials. Whereas early studies (68,69)
showed marked clinical benefits with prazosin compared
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with placebo, more recently published clinical trials (67,70,71)
have shown little difference between prazosin- and placebo-
treated patients, even when therapy is continued for up to
6 months.
Clinical perspective. Resolution of the controversy
concerning the long-term efficacy of prazosin appears un-
likely in the near future. It is probable that the appropriate
role of prazosin in the management of severe heart failure
lies between the extreme positions held by those who con-
sider it to be uniformly beneficial or uniformly useless. In
our experience, prazosin is an effective drug for some pa-
tients; those who do not develop tolerance to its long-term
hemodynamic effects. Unfortunately, this group comprises
only 30 to 40% of consecutively evaluated patients with
severe chronic heart failure (Table 2). It is our belief that,
rather than continuing to pursue the question of efficacy,
future research efforts might more profitably be directed
toward determining the nature of the mechanisms underlying
the development of tolerance and developing means of pre-
venting or reversing its occurrence.
Trimazosin
An analog of prazosin, trimazosin produces similar
hemodynamic effects in patients with severe heart failure
(72-74), presumably by postsynaptic alpha-adrenergic
blockade. As with prazosin, initial reports (75-77) con-
cerning its efficacy have been favorable, but the overall
experience with the drug in severe chronic heart failure is
limited.
Captopril
Therapeutic properties. The orally active angiotensin-
converting enzyme inhibitor, captopril, produces marked
hemodynamic improvement at rest and during exercise in
patients with heart failure, and these effects are similar in
many respects to that seen with other vasodilator drugs
(78-85). Long-term treatment is accompanied by sustained
hemodynamic responses, amelioration of dyspnea and fa-
tigue and enhanced exercise tolerance (81,84,85). The
hemodynamic and clinical benefits of captopril have been
demonstrated in two double-blind placebo-controlled ran-
domized clinical trials (86,87), the most recent of which
was reported in the October issue of this journal. In that
study (87) performed in 92 patients with class III or IV heart
failure, patients treated with captopril had greater improve-
ment in symptoms and in exercise tolerance than did patients
treated with placebo. This multicenter study is the largest
randomized clinical trial of a vasodilator drug in patients
with heart failure completed to date.
Dosage. As with prazosin but in contrast to hydralazine,
determination of an effective dose of captopril is not com-
plicated by highly variable dose requirements. Because only
10 to 20 mg of captopril is needed to completely inhibit the
angiotensin-converting enzyme (88), doses of 25, 50, 100
and 150 mg of the drug produce nearly identical hemody-
namic effects (80,81). The administration of doses greater
than 25 to 50 mg orally may produce hemodynamic re-
sponses of longer duration than those seen with smaller
doses (80,88). However, this enhanced duration has not
been shown to be clinically important and the administration
of larger doses may be associated with a higher frequency
of adverse reactions (89). On the basis of these theoretical
concepts, 25 to 50 mg three times daily may be a uniformly
useful dose of captopril for most patients with severe heart
failure; unfortunately, most of the clinical experience with
the drug in the United States (both in double-blind and
uncontrolled studies) has been with larger doses of the drug
(150 to 300 mg daily).
Acute and long-term hemodynamic effects. Most patients
demonstrate hemodynamic improvement with first doses of
captopril, but the importance of these acute effects remains
unclear. Although the early responses to converting enzyme
inhibition are frequently sustained, the magnitude of these
effects may be enhanced or attenuated during long-term
treatment (90,91). Accordingly, some patients whose con-
dition fails to improve with first doses of captopril show
marked hemodynamic and clinical benefits during long-term
therapy; conversely, some patients with dramatic initial
hemodynamic responses fail to show long-term improve-
ment. This may explain why the short-term hemodynamic
effects of captopril may bear little relation to long-term
changes in exercise tolerance (92-94). This may also ex-
plain why plasma renin activity correlates closely with the
short-term responses to therapy but not with the long-term
effects of the drug (80,95). Because the short-term hemo-
dynamic effects of captopril may become greatly modified
with time, it may not be possible to accurately assess the
therapeutic efficacy of the drug in an individual patient with
severe chronic heart failure for 3 to 6 weeks; this raises
serious questions about the need for invasive hemodynamic
testing during the initiation of therapy with converting en-
zyme inhibitors in patients with severe chronic heart failure
(91,92,94). In our experience (90,91), long-term hemo-
dynamic improvement is seen in approximately 70% of pa-
tients treated with captopril.
Hemodynamic tolerance. Hemodynamic tolerance does
occur during long-term therapy with captopril in some pa-
tients with severe heart failure, but it is uncommon (10 to
15o/c of consecutively treated patients) (91). Such patients
manifest rapid or gradual loss of the hemodynamic benefits
seen with first doses of the drug that is not reversed by
dosage increments; hemodynamic deterioration does not oc-
cur when the drug is withdrawn. Of interest, such patients
are not responsive to alternative inhibitors of the angioten-
sin-converting enzyme, but direct-acting vasodilator drugs
are still effective (96). The incidence of hemodynamic and
clinical tolerance with captopril in heart failure appears to
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besignificantly less common than that seen with hydralazine
or prazosin (97).
Limitations and disadvantages. Three adverse reac-
tions of captopril deserve emphasis . As with other vaso-
dilator drugs, hypotension is a therapeutic effect of captopril
and presents a concern only when accompanied by clinical
evidence of end organ hypoperfusion (dizziness or blurred
vision , or both) ; howe ver , episodes of symptomatic hypo-
tension occur more frequently with captopril than with other
vasodilator drugs (86,89). Such hypoten sive events usually
occur within the first 24 hours of treatment , particularly in
patients who have recently received intravenous diuretic
drugs and those with severe hyponatremia (serum sodium
concentration less than 130 mEq/liter) (89,98); hypona-
tremic patients appear to be dependent on the renin-angi-
otensin system for support of systemic pressure and, thus,
are prone to hypotension when treated with converting en-
zyme inhibitors (99). Hypotension can be avoided by a
reduct ion in the dose of captopril (to 6.25 to 12.5 mg orally)
or of concomitantly administered diuretic drug. A pruritic
erythematous maculopapular rash occurs in 5 to 8% of pa-
tients with heart failure treated with captopril (usually within
6 week s) and is the most common adverse reaction that
necessitate s discontinuation of treatment; occasionally, the
rash will disappear despite continued therapy or will not
recur with rechallenge (100). An increase in blood urea
nitrogen is seen in about 20% of patients with heart failure
treated with captopril (89 ,10I) ; this usually develops in
patients in whom left ventricular filling pressures are ex-
cessively reduced during long-term treatment and is reversed
by a reduction in diuretic dose (101). Although neutropenia
and proteinuria are serious concerns when high doses of
captopril are administered to hypertensive patients with renal
insufficiency (89), these reactions have rarely been seen with
the lower doses of this drug used in the management of
patients with heart failure (86,87). Consequently, as with
nitrates , adverse reactions to captopril are usually manage-
able and uncommonly warrant discontinuation of therapy .
Clinical perspective. In our experience , approximately
60% of patients with severe chronic heart failure improve
during long-term treatment with captopril. This compares
favorabl y with the 30 to 40% respon se rate we have observed
during long-term therapy with hydralazine or with prazosin
(Table 2). Nevertheless, approximately one-third of patient s
with heart failure fail to benefit from captopril therapy , and
the magnitude of clinical improvement in some responders
may be inadequate to restore an individual patient to a useful
life-style (91,93). For these patient s, the addition or sub-
stitution of second line therapy with hydralazine, nitrates
or prazosin may be indicated (9] ,96 ,97,102).
Enalapril
A series of angiotensin-converting enzyme inhibitors are
under development that are analogs of captopril and may
prove useful in the treatment of severe heart failure (103).
The most thoroughly investigated analog, enalapril , has a
longer duration of action than captopril and does not possess
a sulfhydryl group, which has been held responsible for
some of captopril's idiosyncratic adverse effects (104,105 ).
Enalapril produces short- and long-term hemodynamic ben-
efits in patients with severe chronic heart failure similar to
those seen with captopril (106-108) , but experience with
this drug in the treatment of heart failure is still limited .
Whether it will prove as effective as captopril with a lower
incidence of adverse reaction s remains to be determined.
Calcium Channel Antagonists
A number of reports have appeared concerning the ap-
plication of the calcium channel antagonists, nifedipine
(109-111), verapamil (112) and diltiazem (113), as vaso-
dilator drugs in patients with severe chronic heart failure .
Of the three , most of the experience in patients with heart
failure has been gained with nifedipine.
Nifedipine
Like hydralazine and minoxidil, nifedipine is primarily
an arterial vasodilator and , thus, increases cardiac output
and lowers systemic vascular resistance with minimal effects
on right and left ventricular filling pressures (109-111).
Unlike other vasodilator drugs, howe ver , nifedipine exerts
a direct negative inotropic effect on the myocardium, con-
sistent with its ability to block transmembrane calcium trans-
port in cardiac muscle cells (114 ,115). In patients with a
left ventricular ejection fraction greater than 30%, the pe-
ripheral vasodilator effects of nifedipine serve to offset its
negative inotropic effects , so that significant increases in
cardiac output are observed (109-111,116). This is partic-
ularly true in patients with aortic insufficiency or severe
hypertension (1] 7-119), who are exquisitely sensitive to
even small reductions in peripheral resistance. In contrast,
in patients with a left ventricular ejection fraction less than
30%, nifedipine's effects on cardiac performance are un-
predictable . Although increase s in cardiac output may be
seen in such patients , worsening of ventricular performance
may also occur (120,121); in these patients the myocardium
appears to be exquisitely sensitive to pharmacologic depres-
sion and, thus, severe heart failure may be exacerbated by
nifedipine (Table 2) (122). When nifedipine and nitroprus-
side are titrated to produce similar decreases in systemic
vascular resistance in the same patient s with severe heart
failure , the increase in cardiac output and decrease in left
ventricular filling pressure with nitroprusside are greater
than with nifedipine , whereas the hypotensive effects of
nifedipine are greater than with nitroprusside (123). A sim-
ilar deterioration of right ventricular function has been ob-
served after nifedipine in patient s with right heart failure
due to severe pulmonary hypertension (124).
Because the negative inotropic actions of calcium antag-
onists (including nifedipine) may cause worsening of heart
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failure (120,121,124-126) and because experience with these
agents in patients with severe heart failure remains limited,
we do not use calcium antagonists as vasodilators in patients
with severe heart failure unless additional clinical reasons
for their administration exist; angina pectoris or systemic
hypertension, or both.
Inotropic Agents
A number of drugs have been developed over the last 5
years that increase cardiac contractility by mechanisms dis-
tinct from those utilized by digitalis. These include agents
that act by stimulating beta-adrenergic receptors (prenalterol
[127-129], pirbuterol [130-132], salbutamol [133] and ter-
butaline [134]) and agents that act independently of cate-
cholamines (amrinone [135,136], milrinone (WIN 47203)
[137], MDL 17043 [i38] and MDL 19205 [139]). All of
these agents exert peripheral vasodilator actions in addition
to their inotropic effects, either directly or by withdrawal
of reflex vasoconstrictor mechanisms deactivated by the im-
provement in the heart failure state (140-142). The relative
importance of the inotropic versus vasodilator actions of
these drugs in mediating the observed improvement in car-
diac performance remains uncertain.
Beta-Adrenergic Receptor Agonists
The beta-receptor agonist drugs can be categorized into
the beta-receptor agonists (prenalterol), which are thought
to increase cardiac performance by a direct effect on cardiac
contractility mediated by myocardial beta-receptors, and the
betaj-receptor agonists (pirbuterol, salbutamol and terbu-
taline), which are thought to improve cardiac performance
by a systemic vasodilator effect mediated by vascular beta-
receptors (143). Although such selectivity may be present
when low doses of these drugs are administered, the doses
utilized in the treatment of heart failure are large enough
that receptor subselectivity may be lost; hence, it is likely
that both subpopulations of beta-receptors are stimulated by
both groups of drugs (143). Significant increases in cardiac
output and decreases in left ventricular filling pressure at
rest and during exercise occur after short-term therapy with
beta-agonist drugs in patients with severe heart failure
(127-134,144), but this improvement may be accompanied
by significant increases in heart rate (144). Furthermore, in
many patients, the magnitude of hemodynamic benefit is
modest (144), but attempts to increase drug dosage fre-
quently lead to significant adverse reactions (palpitations,
nervousness and tremulousness) (145). In our experience
(132,146), the most serious adverse reactions with beta-
receptor agonists have been their tendency to exacerbate
angina pectoris and provoke ventricular arrhythmias.
The most important limitation of beta-receptor agonist
drugs in the treatment of severe chronic heart failure is the
development of hemodynamic tolerance during long-term
therapy (147-149). Long-term drug administration leads to
a progressive loss of the marked hemodynamic response
seen with initial doses, presumably because of a progressive
decrease in the number of active beta-receptors ("down-
regulation") (149). Although such tolerance is reversible
on discontinuation of the drug, it occurs with sufficient
rapidity (within 1 week) to make effective long-term treat-
ment with these agents unlikely. This probably explains why
double-blind randomized clinical trials of these drugs have
shown little difference between patients treated with an ac-
tive drug and those treated with placebo (Table 2) (145).
Noncatecholamine Inotropic Agents
The noncatecholamine nonglycoside inotropic drugs in-
clude amrinone, milrinone, MDL 17043 and MDL 19205
(135-139). All of these agents directly increase cardiac con-
tractility, but the molecular and biochemical mechanisms
by which these effects are mediated remain unknown (150).
In addition, these drugs produce direct dilator effects on the
peripheral circulation that potentiate the improvement in
cardiac performance (140,141,151).
Amrinone. Of the available agents, most of the clinical
experience has been gained with amrinone. Administered
either intravenously or orally, this inotropic drug produces
marked hemodynamic benefit in most patients with severe
heart failure with little hypotensive risk (135,136,152-154).
Hemodynamic improvement is seen at rest and during ex-
ercise, and exercise tolerance improves with long-term ther-
apy (154-156). However, the role of amrinone in the man-
agement of severe chronic heart failure remains uncertain.
Like hydralazine, the dose requirements of the drug are
variable. Whereas many patients respond to doses of 225
to 300 mg daily, some show little benefit even when 600
mg daily is administered orally (unpublished observations).
This makes empiric therapy with amrinone difficult, and
invasive hemodynamic testing may be necessary to deter-
mine an effective dose of the drug. Although hemodynamic
and clinical deterioration has occurred on withdrawal of
amrinone in some patients (155), others experience little
deterioration when the agent has been discontinued (157);
hence, the development of drug tolerance remains an un-
resolved issue. Adverse effects including gastrointestinal
distress, thrombocytopenia, myalgias, fever, hepatic dys-
function and worsening arrhythmias have been reported with
increasing frequency as experience with amrinone has grown
(151-159). To what extent these can be modified by dose
reduction and to what degree similar adverse effects occur
with other inotropic agents remains to be determined (Table
2). Lastly, there is concern that the long-term administration
of all inotropic drugs may hasten the progression of ven-
tricular dysfunction in patients with severe heart failure and
shorten survival (160); a similar fear has been expressed
with conventional inotropic drugs such as digitalis (161,162).
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Clearly, this new and interesting class of drugs requires
further intensive study.
Conclusions
When the advantages and disadvantages of currently
available drugs for the treatment of severe chronic heart
failure are critically assessed, it appears that long-term con-
verting enzyme inhibition produces more marked and more
consistent hemodynamic and clinical benefits with an ac-
ceptable degree of adverse reactions than do other available
approaches to the management of these patients. It is largely
because of the evidence supporting such a conclusion (in-
cluding the multicenter trial reported in the October issue
of this journal [87]) that the U.S. Food and Drug Admin-
istration approved the use of captopril for patients with
severe chronic heart failure in 1982. Captopril became the
first orally active vasodilator drug to receive such official
approval since the advocacy of oral vasodilator therapy for
patients with heart failure began in earnest 5 years ago.
Despite the great strides made in the past 5 years, how-
ever, our original plea for caution (I) must be made once
again and with even greater conviction. We must remember
that there is still no uniformly effective and safe vasodila-
tor/inotropic drug for the treatment of severe chronic heart
failure and that the development of such an agent in the
future remains unlikely; all currently available agents have
important limitations. The failure of therapy in an individual
patient may be the result of a number of factors: the choice
of an ineffective vasodilator drug; the administration of an
effective drug in subtherapeutic doses; the administration of
an effective drug to improperly selected patients; the failure
of initial hemodynamic benefits to be sustained; the occur-
rence of severe or serious adverse reactions; and the failure
to alter concomitant therapy appropropriately. Furthermore,
no vasodilator drug has been shown to reduce the high
mortality rate that characterizes patients with severe left
ventricular dysfunction (32,33,42).
Each of these limitations must be considered whenever
we read initial enthusiastic reports of a new "break-
through." Early reports of the benefits of a new drug are
commonly expressed with great passion and enthusiasm,
and this enthusiasm is almost always subsequently tempered
by reports of drug failure or adverse reactions. Hence, a
healthy skepticism is always needed when favorable reports
appear. With time, the proper role of a given agent will
emerge, not only from the performance of double-blind
placebo-controlled randomized clinical trials, but from the
scrutiny and clinical experience of the individual physician.
Quotations from the Viking Book of Aphorisms Copyright © 1981 edited
by Auden WH and Kronenberger L. Published by the Viking Press, New
York, New York.
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